{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:19:46Z","timestamp":1791656386621,"version":"4.3.4"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T00:00:00Z","timestamp":1369094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Res"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1038\/cr.2013.70","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T10:37:48Z","timestamp":1369132668000},"page":"746-758","source":"Crossref","is-referenced-by-count":209,"title":["Sirtuin deacetylases in neurodegenerative diseases of aging"],"prefix":"10.1038","volume":"23","author":[{"given":"Adrianna Z","family":"Herskovits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Guarente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,21]]},"reference":[{"key":"BFcr201370_CR1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/genetics\/93.4.877","volume":"93","author":"J Rine","year":"1979","unstructured":"Rine J, Strathern JN, Hicks JB, Herskowitz I . A suppressor of mating-type locus mutations in Saccharomyces cerevisiae: evidence for and identification of cryptic mating-type loci. Genetics 1979; 93:877\u2013901.","journal-title":"Genetics"},{"key":"BFcr201370_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/genetics\/93.1.37","volume":"93","author":"AJ Klar","year":"1979","unstructured":"Klar AJ, Fogel S, Macleod K . MAR1\u2014a regulator of the HMa and HM\u03b1 loci in Saccharomyces cerevisiae. Genetics 1979; 93:37\u201350.","journal-title":"Genetics"},{"key":"BFcr201370_CR3","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1101\/gad.13.19.2570","volume":"13","author":"M Kaeberlein","year":"1999","unstructured":"Kaeberlein M, McVey M, Guarente L . The SIR2\/3\/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13:2570\u20132580.","journal-title":"Genes Dev"},{"key":"BFcr201370_CR4","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1091\/mbc.10.10.3125","volume":"10","author":"S Kim","year":"1999","unstructured":"Kim S, Benguria A, Lai CY, Jazwinski SM . Modulation of life-span by histone deacetylase genes in Saccharomyces cerevisiae. Mol Biol Cell 1999; 10:3125\u20133136.","journal-title":"Mol Biol Cell"},{"key":"BFcr201370_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35001622","volume":"403","author":"S Imai","year":"2000","unstructured":"Imai S, Armstrong CM, Kaeberlein M, Guarente L . Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403:795\u2013800.","journal-title":"Nature"},{"key":"BFcr201370_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0092-8674(00)81671-2","volume":"99","author":"JC Tanny","year":"1999","unstructured":"Tanny JC, Dowd GJ, Huang J, Hilz H, Moazed D . An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing. Cell 1999; 99:735\u2013745.","journal-title":"Cell"},{"key":"BFcr201370_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1006\/bbrc.1999.0897","volume":"260","author":"RA Frye","year":"1999","unstructured":"Frye RA . Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 1999; 260:273\u2013279.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcr201370_CR8","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1126\/science.289.5487.2126","volume":"289","author":"SJ Lin","year":"2000","unstructured":"Lin SJ, Defossez PA, Guarente L . Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 2000; 289:2126\u20132128.","journal-title":"Science"},{"key":"BFcr201370_CR9","doi-asserted-by":"publisher","first-page":"42444","DOI":"10.1074\/jbc.R112.402768","volume":"287","author":"C Sebastian","year":"2012","unstructured":"Sebastian C, Satterstrom FK, Haigis MC, Mostoslavsky R . From sirtuin biology to human diseases: an update. J Biol Chem 2012; 287:42444\u201342452.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nm.2558","volume":"18","author":"M Jiang","year":"2011","unstructured":"Jiang M, Wang J, Fu J, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 2011; 18:153\u2013158.","journal-title":"Nat Med"},{"key":"BFcr201370_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1523\/JNEUROSCI.3442-11.2012","volume":"32","author":"G Donmez","year":"2012","unstructured":"Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L . SIRT1 protects against \u03b1-synuclein aggregation by activating molecular chaperones. J Neurosci 2012; 32:124\u2013132.","journal-title":"J Neurosci"},{"key":"BFcr201370_CR12","doi-asserted-by":"publisher","first-page":"11500","DOI":"10.1523\/JNEUROSCI.3203-08.2008","volume":"28","author":"KN Green","year":"2008","unstructured":"Green KN, Steffan JS, Martinez-Coria H, et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 2008; 28:11500\u201311510.","journal-title":"J Neurosci"},{"key":"BFcr201370_CR13","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1038\/sj.emboj.7601758","volume":"26","author":"D Kim","year":"2007","unstructured":"Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007; 26:3169\u20133179.","journal-title":"EMBO J"},{"key":"BFcr201370_CR14","doi-asserted-by":"publisher","first-page":"21745","DOI":"10.1074\/jbc.M602909200","volume":"281","author":"W Qin","year":"2006","unstructured":"Qin W, Yang T, Ho L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 2006; 281:21745\u201321754.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","volume":"5","author":"M Dokmanovic","year":"2007","unstructured":"Dokmanovic M, Clarke C, Marks PA . Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5:981\u2013989.","journal-title":"Mol Cancer Res"},{"key":"BFcr201370_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","volume":"338","author":"IV Gregoretti","year":"2004","unstructured":"Gregoretti IV, Lee YM, Goodson HV . Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338:17\u201331.","journal-title":"J Mol Biol"},{"key":"BFcr201370_CR17","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.cmet.2011.10.006","volume":"14","author":"MD Hirschey","year":"2011","unstructured":"Hirschey MD . Old enzymes, new tricks: sirtuins are NAD(+)-dependent de-acylases. Cell Metab 2011; 14:718\u2013719.","journal-title":"Cell Metab"},{"key":"BFcr201370_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1006\/bbrc.2000.3000","volume":"273","author":"RA Frye","year":"2000","unstructured":"Frye RA . Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000; 273:793\u2013798.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcr201370_CR19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.1207861","volume":"334","author":"J Du","year":"2011","unstructured":"Du J, Zhou Y, Su X, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 2011; 334:806\u2013809.","journal-title":"Science"},{"key":"BFcr201370_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2006.06.057","volume":"126","author":"MC Haigis","year":"2006","unstructured":"Haigis MC, Mostoslavsky R, Haigis KM, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic \u03b2 cells. Cell 2006; 126:941\u2013954.","journal-title":"Cell"},{"key":"BFcr201370_CR21","doi-asserted-by":"publisher","first-page":"M111 012658","DOI":"10.1074\/mcp.M111.012658","volume":"10","author":"C Peng","year":"2011","unstructured":"Peng C, Lu Z, Xie Z, et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics 2011; 10:M111 012658.","journal-title":"Mol Cell Proteomics"},{"key":"BFcr201370_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.cell.2009.02.026","volume":"137","author":"T Nakagawa","year":"2009","unstructured":"Nakagawa T, Lomb DJ, Haigis MC, Guarente L . SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009; 137:560\u2013570.","journal-title":"Cell"},{"key":"BFcr201370_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nature06736","volume":"452","author":"E Michishita","year":"2008","unstructured":"Michishita E, McCord RA, Berber E, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 2008; 452:492\u2013496.","journal-title":"Nature"},{"key":"BFcr201370_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2005.11.044","volume":"124","author":"R Mostoslavsky","year":"2006","unstructured":"Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006; 124:315\u2013329.","journal-title":"Cell"},{"key":"BFcr201370_CR25","doi-asserted-by":"publisher","first-page":"21313","DOI":"10.1074\/jbc.M413296200","volume":"280","author":"G Liszt","year":"2005","unstructured":"Liszt G, Ford E, Kurtev M, Guarente L . Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J Biol Chem 2005; 280:21313\u201321320.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature11043","volume":"487","author":"MF Barber","year":"2012","unstructured":"Barber MF, Michishita-Kioi E, Xi Y, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 2012; 487:114\u2013118.","journal-title":"Nature"},{"key":"BFcr201370_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1161\/CIRCRESAHA.107.164558","volume":"102","author":"O Vakhrusheva","year":"2008","unstructured":"Vakhrusheva O, Smolka C, Gajawada P, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 2008; 102:703\u2013710.","journal-title":"Circ Res"},{"key":"BFcr201370_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7150\/ijbs.6.599","volume":"6","author":"V Byles","year":"2010","unstructured":"Byles V, Chmilewski LK, Wang J, et al. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K\/IGF-1R signaling in human cancer cells. Int J Biol Sci 2010; 6:599\u2013612.","journal-title":"Int J Biol Sci"},{"key":"BFcr201370_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/jcp.21091","volume":"213","author":"Q Jin","year":"2007","unstructured":"Jin Q, Yan T, Ge X, Sun C, Shi X, Zhai Q . Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol 2007; 213:88\u201397.","journal-title":"J Cell Physiol"},{"key":"BFcr201370_CR30","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1016\/j.febslet.2010.04.063","volume":"584","author":"T Sugino","year":"2010","unstructured":"Sugino T, Maruyama M, Tanno M, Kuno A, Houkin K, Horio Y . Protein deacetylase SIRT1 in the cytoplasm promotes nerve growth factor-induced neurite outgrowth in PC12 cells. FEBS Lett 2010; 584:2821\u20132826.","journal-title":"FEBS Lett"},{"key":"BFcr201370_CR31","doi-asserted-by":"publisher","first-page":"9695","DOI":"10.1523\/JNEUROSCI.0027-10.2010","volume":"30","author":"S Michan","year":"2010","unstructured":"Michan S, Li Y, Chou MM, et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci 2010; 30:9695\u20139707.","journal-title":"J Neurosci"},{"key":"BFcr201370_CR32","doi-asserted-by":"publisher","first-page":"15599","DOI":"10.1073\/pnas.0800612105","volume":"105","author":"S Hisahara","year":"2008","unstructured":"Hisahara S, Chiba S, Matsumoto H, et al. Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci USA 2008; 105:15599\u201315604.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcr201370_CR33","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/sj.onc.1209857","volume":"26","author":"T Inoue","year":"2007","unstructured":"Inoue T, Hiratsuka M, Osaki M, et al. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 2007; 26:945\u2013957.","journal-title":"Oncogene"},{"key":"BFcr201370_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1097-2765(03)00038-8","volume":"11","author":"BJ North","year":"2003","unstructured":"North BJ, Marshall BL, Borra MT, Denu JM, Verdin E . The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003; 11:437\u2013444.","journal-title":"Mol Cell"},{"key":"BFcr201370_CR35","doi-asserted-by":"publisher","first-page":"13653","DOI":"10.1073\/pnas.222538099","volume":"99","author":"P Onyango","year":"2002","unstructured":"Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP . SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci USA 2002; 99:13653\u201313658.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcr201370_CR36","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1101\/gad.1399706","volume":"20","author":"E Ford","year":"2006","unstructured":"Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L . Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev 2006; 20:1075\u20131080.","journal-title":"Genes Dev"},{"key":"BFcr201370_CR37","doi-asserted-by":"crossref","unstructured":"Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012; 8:131\u2013168.","DOI":"10.1016\/j.jalz.2012.02.001"},{"key":"BFcr201370_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nrd3556","volume":"10","author":"DE Ehrnhoefer","year":"2011","unstructured":"Ehrnhoefer DE, Wong BK, Hayden MR . Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nat Rev Drug Discov 2011; 10:853\u2013867.","journal-title":"Nat Rev Drug Discov"},{"key":"BFcr201370_CR39","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S0891-5849(03)00062-5","volume":"34","author":"JH Jang","year":"2003","unstructured":"Jang JH, Surh YJ . Protective effect of resveratrol on \u03b2-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 2003; 34:1100\u20131110.","journal-title":"Free Radic Biol Med"},{"key":"BFcr201370_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.brainresbull.2003.08.001","volume":"62","author":"A Conte","year":"2003","unstructured":"Conte A, Pellegrini S, Tagliazucchi D . Synergistic protection of PC12 cells from \u03b2-amyloid toxicity by resveratrol and catechin. Brain Res Bull 2003; 62:29\u201338.","journal-title":"Brain Res Bull"},{"key":"BFcr201370_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF03033189","volume":"3","author":"AY Sun","year":"2001","unstructured":"Sun AY, Draczynska-Lusiak B, Sun GY . Oxidized lipoproteins, \u03b2 amyloid peptides and Alzheimer's disease. Neurotox Res 2001; 3:167\u2013178.","journal-title":"Neurotox Res"},{"key":"BFcr201370_CR42","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/sj.bjp.0705688","volume":"141","author":"YS Han","year":"2004","unstructured":"Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R . Neuroprotective effects of resveratrol against \u03b2-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 2004; 141:997\u20131005.","journal-title":"Br J Pharmacol"},{"key":"BFcr201370_CR43","first-page":"243","volume":"29","author":"A Conte","year":"2003","unstructured":"Conte A, Pellegrini S, Tagliazucchi D . Effect of resveratrol and catechin on PC12 tyrosine kinase activities and their synergistic protection from \u03b2-amyloid toxicity. Drugs Exp Clin Res 2003; 29:243\u2013255.","journal-title":"Drugs Exp Clin Res"},{"key":"BFcr201370_CR44","doi-asserted-by":"publisher","first-page":"37377","DOI":"10.1074\/jbc.M508246200","volume":"280","author":"P Marambaud","year":"2005","unstructured":"Marambaud P, Zhao H, Davies P . Resveratrol promotes clearance of Alzheimer's disease amyloid-\u03b2 peptides. J Biol Chem 2005; 280:37377\u201337382.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR45","doi-asserted-by":"publisher","first-page":"9100","DOI":"10.1074\/jbc.M109.060061","volume":"285","author":"V Vingtdeux","year":"2010","unstructured":"Vingtdeux V, Giliberto L, Zhao H, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-\u03b2 peptide metabolism. J Biol Chem 2010; 285:9100\u20139113.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neuint.2008.10.008","volume":"54","author":"SS Karuppagounder","year":"2009","unstructured":"Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE . Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 2009; 54:111\u2013118.","journal-title":"Neurochem Int"},{"key":"BFcr201370_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature01960","volume":"425","author":"KT Howitz","year":"2003","unstructured":"Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425:191\u2013196.","journal-title":"Nature"},{"key":"BFcr201370_CR48","doi-asserted-by":"publisher","first-page":"e49761","DOI":"10.1371\/journal.pone.0049761","volume":"7","author":"M Gertz","year":"2012","unstructured":"Gertz M, Nguyen GT, Fischer F, et al. A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One 2012; 7:e49761.","journal-title":"PLoS One"},{"key":"BFcr201370_CR49","doi-asserted-by":"publisher","first-page":"17038","DOI":"10.1074\/jbc.M500655200","volume":"280","author":"M Kaeberlein","year":"2005","unstructured":"Kaeberlein M, McDonagh T, Heltweg B, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 2005; 280:17038\u201317045.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR50","doi-asserted-by":"publisher","first-page":"8340","DOI":"10.1074\/jbc.M109.088682","volume":"285","author":"M Pacholec","year":"2010","unstructured":"Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010; 285:8340\u20138351.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR51","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1042\/BJ20070236","volume":"406","author":"S Frojdo","year":"2007","unstructured":"Frojdo S, Cozzone D, Vidal H, Pirola L . Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J 2007; 406:511\u2013518.","journal-title":"Biochem J"},{"key":"BFcr201370_CR52","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","volume":"127","author":"M Lagouge","year":"2006","unstructured":"Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1\u03b1. Cell 2006; 127:1109\u20131122.","journal-title":"Cell"},{"key":"BFcr201370_CR53","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.1073\/pnas.0610068104","volume":"104","author":"B Dasgupta","year":"2007","unstructured":"Dasgupta B, Milbrandt J . Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007; 104:7217\u20137222.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcr201370_CR54","doi-asserted-by":"publisher","first-page":"17187","DOI":"10.1074\/jbc.M501250200","volume":"280","author":"MT Borra","year":"2005","unstructured":"Borra MT, Smith BC, Denu JM . Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005; 280:17187\u201317195.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR55","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1747-0285.2009.00901.x","volume":"74","author":"D Beher","year":"2009","unstructured":"Beher D, Wu J, Cumine S, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009; 74:619\u2013624.","journal-title":"Chem Biol Drug Des"},{"key":"BFcr201370_CR56","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1126\/science.1231097","volume":"339","author":"BP Hubbard","year":"2013","unstructured":"Hubbard BP, Gomes AP, Dai H, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013; 339:1216\u20131219.","journal-title":"Science"},{"key":"BFcr201370_CR57","doi-asserted-by":"publisher","first-page":"40364","DOI":"10.1074\/jbc.M509329200","volume":"280","author":"J Chen","year":"2005","unstructured":"Chen J, Zhou Y, Mueller-Steiner S, et al. SIRT1 protects against microglia-dependent amyloid-\u03b2 toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280:40364\u201340374.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR58","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1126\/science.1090154","volume":"302","author":"Y Zhou","year":"2003","unstructured":"Zhou Y, Su Y, Li B, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic A\u03b242 by inhibiting Rho. Science 2003; 302:1215\u20131217.","journal-title":"Science"},{"key":"BFcr201370_CR59","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2010.06.020","volume":"142","author":"G Donmez","year":"2010","unstructured":"Donmez G, Wang D, Cohen DE, Guarente L . SIRT1 suppresses \u03b2-amyloid production by activating the \u03b1-secretase gene ADAM10. Cell 2010; 142:320\u2013332.","journal-title":"Cell"},{"key":"BFcr201370_CR60","unstructured":"Prayson RA . Neuropathology. Philadelphia: Elsevier, 2005."},{"key":"BFcr201370_CR61","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0896-6273(03)00627-5","volume":"40","author":"JC Cruz","year":"2003","unstructured":"Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH . Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003; 40:471\u2013483.","journal-title":"Neuron"},{"key":"BFcr201370_CR62","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","volume":"67","author":"SW Min","year":"2010","unstructured":"Min SW, Cho SH, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010; 67:953\u2013966.","journal-title":"Neuron"},{"key":"BFcr201370_CR63","unstructured":"Min SW, Sohn P, Devidze N, et al. Sirt1 deficiency in the brain increases tau acetylation and exacerbates cognitive deficits in a mouse model of tauopathy. Society for Neuroscience 2012 Neuroscience Meeting Planner: New Orleans, LA 2012."},{"key":"BFcr201370_CR64","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/ncomms1255","volume":"2","author":"TJ Cohen","year":"2011","unstructured":"Cohen TJ, Guo JL, Hurtado DE, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2011; 2:252.","journal-title":"Nat Commun"},{"key":"BFcr201370_CR65","unstructured":"Resveratrol for Alzheimer's Disease. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01504854 Accessed: December 31, 2012."},{"key":"BFcr201370_CR66","unstructured":"Randomized Trial of a Nutritional Supplement in Alzheimer's Disease. Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00678431 Accessed: January 1, 2013."},{"key":"BFcr201370_CR67","unstructured":"Short term efficacy and safety of perispinal administration of etanercept in mild to moderate Alzheimer's disease. Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show?term=resveratrol&cond=%22Alzheimer+Disease%22&rank=4 Accessed: January 1, 2013."},{"key":"BFcr201370_CR68","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM . Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5:525\u2013535.","journal-title":"Lancet Neurol"},{"key":"BFcr201370_CR69","doi-asserted-by":"crossref","unstructured":"Blesa J, Phani S, Jackson-Lewis V, Przedborski S . Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012; 2012:845618.","DOI":"10.1155\/2012\/845618"},{"key":"BFcr201370_CR70","doi-asserted-by":"publisher","first-page":"e1000027","DOI":"10.1371\/journal.pgen.1000027","volume":"4","author":"TJ van Ham","year":"2008","unstructured":"van Ham TJ, Thijssen KL, Breitling R, Hofstra RM, Plasterk RH, Nollen EA . C. elegans model identifies genetic modifiers of \u03b1-synuclein inclusion formation during aging. PLoS Genet 2008; 4:e1000027.","journal-title":"PLoS Genet"},{"key":"BFcr201370_CR71","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000328516","volume":"19","author":"Y Wu","year":"2011","unstructured":"Wu Y, Li X, Zhu JX, et al. Resveratrol-activated AMPK\/SIRT1\/autophagy in cellular models of Parkinson's disease. Neurosignals 2011; 19:163\u2013174.","journal-title":"Neurosignals"},{"key":"BFcr201370_CR72","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/j.1471-4159.2009.06228.x","volume":"110","author":"D Albani","year":"2009","unstructured":"Albani D, Polito L, Batelli S, et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by \u03b1-synuclein or amyloid-\u03b2 (1ndash;42) peptide. J Neurochem 2009; 110:1445\u20131456.","journal-title":"J Neurochem"},{"key":"BFcr201370_CR73","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.pnpbp.2008.03.024","volume":"32","author":"J Blanchet","year":"2008","unstructured":"Blanchet J, Longpre F, Bureau G, et al. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1243\u20131250.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFcr201370_CR74","doi-asserted-by":"publisher","first-page":"29045","DOI":"10.1074\/jbc.M112.353714","volume":"287","author":"R Raynes","year":"2012","unstructured":"Raynes R, Leckey BD Jr, Nguyen K, Westerheide SD . Heat shock and caloric restriction have a synergistic effect on the heat shock response in a sir2.1-dependent manner in Caenorhabditis elegans. J Biol Chem 2012; 287:29045\u201329053.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR75","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1126\/science.1165946","volume":"323","author":"SD Westerheide","year":"2009","unstructured":"Westerheide SD, Anckar J, Stevens SM Jr, Sistonen L, Morimoto RI . Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 2009; 323:1063\u20131066.","journal-title":"Science"},{"key":"BFcr201370_CR76","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1126\/science.1143780","volume":"317","author":"TF Outeiro","year":"2007","unstructured":"Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors rescue \u03b1-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007; 317:516\u2013519.","journal-title":"Science"},{"key":"BFcr201370_CR77","doi-asserted-by":"publisher","first-page":"32307","DOI":"10.1074\/jbc.C112.403048","volume":"287","author":"L Liu","year":"2012","unstructured":"Liu L, Arun A, Ellis L, Peritore C, Donmez G . Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein. J Biol Chem 2012; 287:32307\u201332311.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR78","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nm.2624","volume":"18","author":"AR La Spada","year":"2012","unstructured":"La Spada AR . Finding a sirtuin truth in Huntington's disease. Nat Med 2012; 18:24\u201326.","journal-title":"Nat Med"},{"key":"BFcr201370_CR79","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/ng1534","volume":"37","author":"JA Parker","year":"2005","unstructured":"Parker JA, Arango M, Abderrahmane S, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 2005; 37:349\u2013350.","journal-title":"Nat Genet"},{"key":"BFcr201370_CR80","doi-asserted-by":"publisher","first-page":"12630","DOI":"10.1523\/JNEUROSCI.0277-12.2012","volume":"32","author":"JA Parker","year":"2012","unstructured":"Parker JA, Vazquez-Manrique RP, Tourette C, et al. Integration of \u03b2-catenin, sirtuin, and FOXO signaling protects from mutant huntingtin toxicity. J Neurosci 2012; 32:12630\u201312640.","journal-title":"J Neurosci"},{"key":"BFcr201370_CR81","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","volume":"17","author":"J Pallos","year":"2008","unstructured":"Pallos J, Bodai L, Lukacsovich T, et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 2008; 17:3767\u20133775.","journal-title":"Hum Mol Genet"},{"key":"BFcr201370_CR82","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/00008877-200609000-00014","volume":"17","author":"P Kumar","year":"2006","unstructured":"Kumar P, Padi SS, Naidu PS, Kumar A . Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol 2006; 17:485\u2013492.","journal-title":"Behav Pharmacol"},{"key":"BFcr201370_CR83","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","volume":"225","author":"DJ Ho","year":"2010","unstructured":"Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF . Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol 2010; 225:74\u201384.","journal-title":"Exp Neurol"},{"key":"BFcr201370_CR84","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nm.2559","volume":"18","author":"H Jeong","year":"2011","unstructured":"Jeong H, Cohen DE, Cui L, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 2011; 18:159\u2013165.","journal-title":"Nat Med"},{"key":"BFcr201370_CR85","doi-asserted-by":"publisher","first-page":"7927","DOI":"10.1073\/pnas.1002924107","volume":"107","author":"R Luthi-Carter","year":"2010","unstructured":"Luthi-Carter R, Taylor DM, Pallos J, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA 2010; 107:7927\u20137932.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcr201370_CR86","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.celrep.2012.11.001","volume":"2","author":"V Chopra","year":"2012","unstructured":"Chopra V, Quinti L, Kim J, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep 2012; 2:1492\u20131497.","journal-title":"Cell Rep"},{"key":"BFcr201370_CR87","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.tins.2011.06.005","volume":"34","author":"M Valenza","year":"2011","unstructured":"Valenza M, Cattaneo E . Emerging roles for cholesterol in Huntington's disease. Trends Neurosci 2011; 34:474\u2013486.","journal-title":"Trends Neurosci"},{"key":"BFcr201370_CR88","doi-asserted-by":"publisher","first-page":"e34805","DOI":"10.1371\/journal.pone.0034805","volume":"7","author":"A Bobrowska","year":"2012","unstructured":"Bobrowska A, Donmez G, Weiss A, Guarente L, Bates G . SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS One 2012; 7:e34805.","journal-title":"PLoS One"},{"key":"BFcr201370_CR89","doi-asserted-by":"publisher","first-page":"24460","DOI":"10.1074\/jbc.M112.382226","volume":"287","author":"J Fu","year":"2012","unstructured":"Fu J, Jin J, Cichewicz RH, et al. trans-(-)-\u03b5-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington disease. J Biol Chem 2012; 287:24460\u201324472.","journal-title":"J Biol Chem"},{"key":"BFcr201370_CR90","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59\u201362.","journal-title":"Nature"},{"key":"BFcr201370_CR91","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314:130\u2013133.","journal-title":"Science"},{"key":"BFcr201370_CR92","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","volume":"351","author":"T Arai","year":"2006","unstructured":"Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006; 351:602\u2013611.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcr201370_CR93","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1126\/science.1166066","volume":"323","author":"TJ Kwiatkowski Jr.","year":"2009","unstructured":"Kwiatkowski TJ, Jr., Bosco DA, Leclerc AL, et al. Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323:1205\u20131208.","journal-title":"Science"},{"key":"BFcr201370_CR94","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1212\/01.wnl.0000200048.53766.b4","volume":"66","author":"M Morita","year":"2006","unstructured":"Morita M, Al-Chalabi A, Andersen PM, et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006; 66:839\u2013844.","journal-title":"Neurology"},{"key":"BFcr201370_CR95","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72:245\u2013256.","journal-title":"Neuron"},{"key":"BFcr201370_CR96","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72:257\u2013268.","journal-title":"Neuron"},{"key":"BFcr201370_CR97","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/brain\/awl030","volume":"129","author":"C Vance","year":"2006","unstructured":"Vance C, Al-Chalabi A, Ruddy D, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2\u201321.3. Brain 2006; 129 (Pt 4):868\u2013876.","journal-title":"Brain"},{"key":"BFcr201370_CR98","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/WCO.0b013e32835a309d","volume":"25","author":"M Gladman","year":"2012","unstructured":"Gladman M, Cudkowicz M, Zinman L . Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis. Curr Opin Neurol 2012; 25:735\u2013742.","journal-title":"Curr Opin Neurol"},{"key":"BFcr201370_CR99","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.21147","volume":"61","author":"IR Mackenzie","year":"2007","unstructured":"Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61:427\u2013434.","journal-title":"Ann Neurol"},{"key":"BFcr201370_CR100","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nature10353","volume":"477","author":"HX Deng","year":"2011","unstructured":"Deng HX, Chen W, Hong ST, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS\/dementia. Nature 2011; 477:211\u2013215.","journal-title":"Nature"},{"key":"BFcr201370_CR101","doi-asserted-by":"publisher","first-page":"2949.e13","DOI":"10.1016\/j.neurobiolaging.2012.07.002","volume":"33","author":"M Synofzik","year":"2012","unstructured":"Synofzik M, Maetzler W, Grehl T, et al. Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. Neurobiol Aging 2012; 33:2949.e13\u20132949.e17.","journal-title":"Neurobiol Aging"},{"key":"BFcr201370_CR102","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","volume":"11","author":"E Majounie","year":"2012","unstructured":"Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11:323\u2013330.","journal-title":"Lancet Neurol"},{"key":"BFcr201370_CR103","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/nn.2660","volume":"13","author":"DA Bosco","year":"2010","unstructured":"Bosco DA, Morfini G, Karabacak NM, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010; 13:1396\u20131403.","journal-title":"Nat Neurosci"},{"key":"BFcr201370_CR104","doi-asserted-by":"publisher","first-page":"e35050","DOI":"10.1371\/journal.pone.0035050","volume":"7","author":"E Pokrishevsky","year":"2012","unstructured":"Pokrishevsky E, Grad LI, Yousefi M, Wang J, Mackenzie IR, Cashman NR . Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One 2012; 7:e35050.","journal-title":"PLoS One"},{"key":"BFcr201370_CR105","doi-asserted-by":"publisher","first-page":"12524","DOI":"10.1073\/pnas.0705044104","volume":"104","author":"A Gruzman","year":"2007","unstructured":"Gruzman A, Wood WL, Alpert E, et al. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2007; 104:12524\u201312529.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcr201370_CR106","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.neulet.2011.08.047","volume":"503","author":"J Wang","year":"2011","unstructured":"Wang J, Zhang Y, Tang L, Zhang N, Fan D . Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Neurosci Lett 2011; 503:250\u2013255.","journal-title":"Neurosci Lett"},{"key":"BFcr201370_CR107","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.brainres.2011.09.025","volume":"1423","author":"M Y\u00e1\u00f1ez","year":"2011","unstructured":"Y\u00e1\u00f1ez M, Gal\u00e1n L, Mat\u00edas-Guiu J, Vela A, Guerrero A, Garc\u00eda AG . CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole. Brain Res 2011; 1423:77\u201386.","journal-title":"Brain Res"},{"key":"BFcr201370_CR108","unstructured":"Gold Standard, Inc. Riluzole. Clinical Pharmacology [online database]. Available at: http:\/\/www.clinicalpharmacology.com Accessed: January 27, 2013."},{"key":"BFcr201370_CR109","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1126\/science.8209258","volume":"264","author":"ME Gurney","year":"1994","unstructured":"Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264:1772\u20131775.","journal-title":"Science"},{"key":"BFcr201370_CR110","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1089\/jmf.2009.0243","volume":"13","author":"CD Markert","year":"2010","unstructured":"Markert CD, Kim E, Gifondorwa DJ, Childers MK, Milligan CE . A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J Med Food 2010; 13:1081\u20131085.","journal-title":"J Med Food"},{"key":"BFcr201370_CR111","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.brainres.2012.09.022","volume":"1483","author":"S Han","year":"2012","unstructured":"Han S, Choi JR, Soon Shin K, Kang SJ . Resveratrol upregulated heat shock proteins and extended the survival of G93A-SOD1 mice. Brain Res 2012; 1483:112\u2013117.","journal-title":"Brain Res"},{"key":"BFcr201370_CR112","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jconrel.2011.09.083","volume":"158","author":"A Amri","year":"2012","unstructured":"Amri A, Chaumeil JC, Sfar S, Charrueau C . Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release 2012; 158:182\u2013193.","journal-title":"J Control Release"},{"key":"BFcr201370_CR113","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.brainres.2011.11.019","volume":"1433","author":"JC Lee","year":"2012","unstructured":"Lee JC, Shin JH, Park BW, et al. Region-specific changes in the immunoreactivity of SIRT1 expression in the central nervous system of SOD1(G93A) transgenic mice as an in vivo model of amyotrophic lateral sclerosis. Brain Res 2012; 1433:20\u201328.","journal-title":"Brain Res"},{"key":"BFcr201370_CR114","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000338048","volume":"11","author":"S K\u00f6rner","year":"2013","unstructured":"K\u00f6rner S, B\u00f6selt S, Thau N, Rath KJ, Dengler R, Petri S . Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? Neurodegener Dis 2013; 11:141\u2013152.","journal-title":"Neurodegener Dis"},{"key":"BFcr201370_CR115","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.nbd.2012.07.004","volume":"51","author":"W Song","year":"2013","unstructured":"Song W, Song Y, Kincaid B, Bossy B, Bossy-Wetzel E . Mutant SOD1(G93A) triggers mitochondrial fragmentation in spinal cord motor neurons: Neuroprotection by SIRT3 and PGC-1\u03b1. Neurobiol Dis 2013; 51:72\u201381.","journal-title":"Neurobiol Dis"},{"key":"BFcr201370_CR116","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/nm.2967","volume":"18","author":"DE Merry","year":"2012","unstructured":"Merry DE . Attacking the flank: targeting new pathways in SBMA. Nat Med 2012; 18:1461\u20131463.","journal-title":"Nat Med"},{"key":"BFcr201370_CR117","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-61779-243-4_1","volume":"776","author":"AO Brinkmann","year":"2011","unstructured":"Brinkmann AO . Molecular mechanisms of androgen action--a historical perspective. Methods Mol Biol 2011; 776:3\u201324.","journal-title":"Methods Mol Biol"},{"key":"BFcr201370_CR118","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/352077a0","volume":"352","author":"AR La Spada","year":"1991","unstructured":"La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH . Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352:77\u201379.","journal-title":"Nature"},{"key":"BFcr201370_CR119","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0896-6273(02)00834-6","volume":"35","author":"M Katsuno","year":"2002","unstructured":"Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002; 35:843\u2013854.","journal-title":"Neuron"},{"key":"BFcr201370_CR120","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nm878","volume":"9","author":"M Katsuno","year":"2003","unstructured":"Katsuno M, Adachi H, Doyu M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003; 9:768\u2013773.","journal-title":"Nat Med"},{"key":"BFcr201370_CR121","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S1474-4422(10)70321-5","volume":"10","author":"LE Fernandez-Rhodes","year":"2011","unstructured":"Fernandez-Rhodes LE, Kokkinis AD, White MJ, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol 2011; 10:140\u2013147.","journal-title":"Lancet Neurol"},{"key":"BFcr201370_CR122","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S1474-4422(10)70182-4","volume":"9","author":"M Katsuno","year":"2010","unstructured":"Katsuno M, Banno H, Suzuki K, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9:875\u2013884.","journal-title":"Lancet Neurol"},{"key":"BFcr201370_CR123","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1128\/MCB.00289-06","volume":"26","author":"M Fu","year":"2006","unstructured":"Fu M, Liu M, Sauve AA, et al. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol 2006; 26:8122\u20138135.","journal-title":"Mol Cell Biol"},{"key":"BFcr201370_CR124","doi-asserted-by":"publisher","first-page":"17425","DOI":"10.1523\/JNEUROSCI.3958-11.2011","volume":"31","author":"HL Montie","year":"2011","unstructured":"Montie HL, Pestell RG, Merry DE . SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA. J Neurosci 2011; 31:17425\u201317436.","journal-title":"J Neurosci"},{"key":"BFcr201370_CR125","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/onc.2011.347","volume":"31","author":"F Wang","year":"2012","unstructured":"Wang F, Chan CH, Chen K, Guan X, Lin HK, Tong Q . Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene 2012; 31:1546\u20131557.","journal-title":"Oncogene"},{"key":"BFcr201370_CR126","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.febslet.2008.06.031","volume":"582","author":"T Kahyo","year":"2008","unstructured":"Kahyo T, Mostoslavsky R, Goto M, Setou M . Sirtuin-mediated deacetylation pathway stabilizes Werner syndrome protein. FEBS Lett 2008; 582:2479\u20132483.","journal-title":"FEBS Lett"},{"key":"BFcr201370_CR127","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.nbd.2007.07.004","volume":"28","author":"M Valenza","year":"2007","unstructured":"Valenza M, Leoni V, Tarditi A, et al. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6\/2 mouse model of Huntington's disease. Neurobiol Dis 2007; 28:133\u2013142.","journal-title":"Neurobiol Dis"}],"container-title":["Cell Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cr201370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cr201370","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cr201370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:33:26Z","timestamp":1684416806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cr201370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,21]]},"references-count":127,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["BFcr201370"],"URL":"https:\/\/doi.org\/10.1038\/cr.2013.70","relation":{},"ISSN":["1001-0602","1748-7838"],"issn-type":[{"value":"1001-0602","type":"print"},{"value":"1748-7838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,21]]}}}